Form 4: Evolent Health Director Russell Glass Receives Equity Grant Valued at $0 for 21,979 Restricted Stock Units

Evolent Health, Inc. Director Russell Monroe Glass was granted 21,979 restricted stock units (RSUs) as part of his compensation, vesting in 2026.

Summary

• Russell Monroe Glass, a Director of Evolent Health, Inc. (EVH), acquired 21,979 Class A Common Stock shares on June 5, 2025, through a restricted stock unit (RSU) grant.
• The acquisition price for these RSUs was $0, indicating they were granted as compensation rather than purchased.
• These restricted stock units were granted pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The securities are scheduled to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent upon Mr. Glass's continued service.
• Following this transaction, Mr. Glass directly beneficially owns 36,251 Class A Common Stock shares.
• Additionally, 6,046 Class A Common Stock shares are indirectly beneficially owned by Mr. Glass through a trust, where he and his spouse serve as co-trustees with shared voting and dispositive power.

Sentiment

Score: 7

Explanation: The sentiment is positive for the director as he received a significant equity grant. For the company, it's a neutral to slightly positive event as it represents standard compensation and aligns director interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The grant of restricted stock units to Director Russell Monroe Glass aligns his interests with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• This equity grant is a standard component of director compensation, indicating a stable and ongoing relationship between the director and the company.

Future Outlook

The restricted stock units granted to Director Russell Monroe Glass are set to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent on his continued service.

Industry Context

In the healthcare technology and services industry, it is common practice for publicly traded companies like Evolent Health to use equity-based compensation, such as restricted stock units, to attract, retain, and incentivize directors and executives. This practice helps align the interests of leadership with long-term shareholder value creation.

Related Party Transactions

• The acquisition of 21,979 Class A Common Stock shares by Director Russell Monroe Glass at a price of $0 represents a related party transaction, as it is an equity grant from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, as the value of his compensation is tied to the company's stock performance.
• Employees: While not directly impacting employees, such compensation practices are part of a broader corporate governance framework that can influence overall company culture and performance.

Next Steps

• The 21,979 restricted stock units granted to Mr. Glass will vest on the earlier of June 5, 2026, or the date of Evolent Health's 2026 annual meeting, provided he continues his service as a director.

Key Dates

Keywords

Evolent Health, EVH, Russell Monroe Glass, Director, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, Form 4, Compensation Plan, Corporate Governance